Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 | Synapse
September 10, 2025Open Access
Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Key Points
On-treatment changes in CD8+ CM cells correlate with best overall response in advanced melanoma patients.
Alterations in CD4+ EM cell populations are also associated with patient outcomes, highlighting their importance.